Opendata, web and dolomites

EBOVAC3 SIGNED

Bringing a prophylactic Ebola vaccine to licensure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EBOVAC3" data sheet

The following table provides information about the project.

Coordinator
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER 

Organization address
address: KEPPEL STREET
city: LONDON
postcode: WC1E 7HT
website: http://www.lshtm.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 29˙402˙655 €
 EC max contribution 29˙402˙655 € (100%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-08-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) coordinator 11˙261˙968.00
2    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 8˙541˙212.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 4˙835˙026.00
4    UNIVERSITY OF SIERRA LEONE SL (FREETOWN) participant 4˙764˙447.00
5    COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION NO (OSLO) participant 0.00
6    JANSSEN VACCINES & PREVENTION BV NL (LEIDEN) participant 0.00

Map

 Project objective

The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:

“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOVAC3" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOVAC3" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More